• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 1-Z filed by Scopus BioPharma Inc.

    2/9/24 5:15:27 PM ET
    $SCPS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SCPS alert in real time by email
    schemaVersion:
    Form 1-Z Issuer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM 1-Z
    EXIT REPORT UNDER REGULATION A
    OMB APPROVAL


    FORM 1-Z

    OMB Number:  3235-0723


    Estimated average burden hours per response: 1.5

    1-Z: Filer Information

    Issuer CIK
    0001772028 
    Issuer CCC
    XXXXXXXX 
    File Number
     
    Is this filing by a successor company pursuant to Rule 257(b)(5) resulting from a merger or other business combination? Radio button not checked Yes Radio button checked No
    Successor File Number
     
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST
    Is this an electronic copy of an official filing submitted in paper format? Checkbox not checked
    Would you like a Return Copy? Checkbox not checked

    Submission Contact Information

    Name
     
    Phone
     
    E-Mail Address
     
    Notify via Filing Website only? Checkbox not checked

    1-Z: PRELIMINARY INFORMATION

    Exact name of issuer as specified in the issuer's charter

    Scopus BioPharma Inc. 

    Address of Principal Executive Offices
    Address 1

    420 LEXINGTON AVENUE, SUITE 300 

    Address 2

     

    City

    NEW YORK 

    State/Country

    NEW YORK  

    Mailing Zip/ Postal Code

    10170 

    Phone

    212-479-2513 

    Commission File Number(s)

    024-11137 

    Commission File Number(s)

    024-11228 

    1-Z: PART II Certification of Suspension of Duty to File Reports

    Certification

    Title of each class of securities covered by this Form

    Series A Units; Common Stock, par value $0.001 per share

    Commission File Number(s)

    024-11137 

    Commission File Number(s)

    024-11228 

    Approximate number of holders of record as of the certification date

    251 

    1-Z: Signature

    Signature

    Pursuant to the requirements of Regulation A,

    Cik

    0001772028 

    (Name of issuer as specified in charter)

    Scopus BioPharma Inc.

    certifies that it meets all of the conditions for termination of Regulation A reporting specified in Rule 257(d) and that there are no classes of securities other than those that are the subject to this Form 1-Z regarding which the issuer has Regulation A reporting obligations.

    (Name of issuer as specified in charter)

    Scopus BioPharma Inc.

    Has caused this certification to be signed on its behalf by the undersigned duly authorized person.

    By

    /s/ Joshua R. Lamstein 

    Date

    02-09-2024 

    Title

    Chairman

    Instructions: This Part II of Form 1-Z is required by Rule 257(d) of Regulation A. An officer of the issuer or any other duly authorized person may sign, and must do so by typed signature. The name and title of the person signing the form must be typed or printed under the signature. The signatory to the filing must also manually sign a signature page or other document authenticating, acknowledging or otherwise adopting his or her signature that appears in the filing. Such document must be executed before or at the time the filing is made and must be retained by the issuer for a period of five years. Upon request, the issuer must furnish to the Commission or its staff a copy of any or all documents retained pursuant to this instruction.

    Get the next $SCPS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SCPS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SCPS
    SEC Filings

    See more
    • SEC Form 1-Z filed by Scopus BioPharma Inc.

      1-Z - Scopus BioPharma Inc. (0001772028) (Filer)

      2/9/24 5:15:27 PM ET
      $SCPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 15-12G filed by Scopus BioPharma Inc.

      15-12G - Scopus BioPharma Inc. (0001772028) (Filer)

      1/19/24 5:15:20 PM ET
      $SCPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scopus BioPharma Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - Scopus BioPharma Inc. (0001772028) (Filer)

      8/18/23 5:16:15 PM ET
      $SCPS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCPS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Greenspan Ira Scott

      4 - Scopus BioPharma Inc. (0001772028) (Issuer)

      11/26/21 5:01:25 PM ET
      $SCPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Lamstein Joshua R

      4 - Scopus BioPharma Inc. (0001772028) (Issuer)

      11/26/21 5:01:05 PM ET
      $SCPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Hopper Paul acquired 706,333 shares, increasing direct ownership by 100% to 12,666 units

      4 - Scopus BioPharma Inc. (0001772028) (Issuer)

      11/17/21 9:48:52 AM ET
      $SCPS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCPS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Scopus BioPharma's Subsidiary — Duet BioTherapeutics — Presents Compelling New Data for a Novel Treatment for Malignant Glioma at 38th Annual Meeting of the Society for Immunotherapy of Cancer

      DUET-102 in Combination with PD-1 Blockade Demonstrates Significant Anti-Tumor Activity in Models of Malignant Glioma Data Suggests Benefits of Combinations of DUET-102 with Other T-Cell Based Immunotherapies, such as CAR-Ts NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (OTCQB: "SCPS") and its majority-owned subsidiary, Duet BioTherapeutics Inc., presented compelling new data that DUET-102 in combination with PD-1 blockade demonstrates significant anti-tumor activity in models of malignant glioma. The new data was presented on November 4, 2023 at the 38th Annual Meeting of the Society for Immunotherapy of Cancer ("SITC") by Marcin Kortylewski, Ph.D. Dr. Kortylewski,

      11/7/23 9:15:00 AM ET
      $SCPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scopus BioPharma's Subsidiary — Duet BioTherapeutics — to Present at the 38th Annual Meeting of the Society for Immunotherapy of Cancer

      NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (OTCQB: "SCPS"), a biotechnology company developing transformational therapeutics for serious diseases with significant unmet medical need, and its subsidiary, Duet BioTherapeutics Inc., which is developing novel immunotherapies to overcome treatment-resistant cancers, today announced that Marcin Kortylewski, Ph.D., Co-Founder and Senior Scientific Advisor of Duet and Professor of Immuno-Oncology at City of Hope, will be presenting at the 38th Annual Meeting of the Society for Immunotherapy of Cancer ("SITC"). SITC is being held from November 3-5, 2023, in San Diego, California. Details of the presentation are as follows:

      11/2/23 9:15:00 AM ET
      $SCPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scopus BioPharma's Subsidiary — Duet BioTherapeutics — Announces Key Scientific Data to be Presented at the 37th Annual Meeting and Exposition of the Society for Immunotherapy of Cancer

      NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: "SCPS"), a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, and its pure-play immuno-oncology subsidiary, Duet BioTherapeutics, today announced that key scientific data will be will be presented at the 37th Annual Meeting and Exposition of the Society for Immunotherapy of Cancer ("SITC"). SITC is being held from November 8-12, 2022 at the Boston Convention and Exhibition Center in Boston, Massachusetts. About Scopus BioPharma Scopus BioPharma Inc. is a biopharmaceutical company developing transformational therapeutics for serious diseases

      11/10/22 9:15:00 AM ET
      $SCPS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCPS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Scopus BioPharma Inc.

      SC 13D - Scopus BioPharma Inc. (0001772028) (Subject)

      11/26/21 5:04:51 PM ET
      $SCPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Scopus BioPharma Inc. (Amendment)

      SC 13D/A - Scopus BioPharma Inc. (0001772028) (Subject)

      11/26/21 5:00:40 PM ET
      $SCPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Scopus BioPharma Inc. (Amendment)

      SC 13D/A - Scopus BioPharma Inc. (0001772028) (Subject)

      11/26/21 5:00:10 PM ET
      $SCPS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCPS
    Financials

    Live finance-specific insights

    See more
    • Scopus BioPharma Expands Immunotherapy Pipeline with Acquisition of Olimmune

      Transaction Creates Global Leader in Oligonucleotide Cancer Therapeutics Combined Assets Target Broad Range of Hematological Malignancies and Solid Tumors NEW YORK, June 30, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: "SCPS"), a clinical-stage biopharmaceutical company developing transformational therapeutics, today announced the acquisition of Los Angeles-based Olimmune Inc. Olimmune is a developer of groundbreaking oligonucleotide immunotherapies for treatment-resistant and metastatic cancers. Olimmune's lead drug candidate, OLIM-01, is being developed for genitourinary and head and neck cancers. It is anticipated that INDs for these indications will be submitt

      6/30/21 9:30:00 AM ET
      $SCPS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCPS
    Leadership Updates

    Live Leadership Updates

    See more
    • Scopus BioPharma Announces Biotechnology Industry Leader Rejoins Board of Directors

      NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: "SCPS"), a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announced the appointment of Raphael ("Rafi") Hofstein, Ph.D. to its Board of Directors ("Board"). Joshua R. Lamstein, Chairman of Scopus BioPharma, stated, "We are thrilled Dr. Hofstein is rejoining our Board. Dr. Hofstein brings invaluable insights and unparalleled experience in building start-up biotechnology companies into industry leaders." Dr. Hofstein is a global leader in the biopharmaceutical and biotechnology industries. Over his career, Dr. Hofstein has been in

      5/5/22 8:30:00 AM ET
      $SCPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scopus BioPharma Provides Update Following Annual Meeting of Stockholders

      Overwhelming Majority of Shares Voted by Unaffiliated Stockholderswere in Favor of Scopus' Director Nominees Lasters' Ownership Position and Annual Meeting Results are being Challenged in Court Company Believes Ultimate Outcome of Annual Meeting Will Depend on Results of Pending Cases NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (NASDAQ:SCPS) ("Scopus" or the "Company") today announced that it has filed an amendment to the Current Report on Form 8-K that was filed by the Company on December 27, 2021 with the U.S. Securities and Exchange Commission disclosing the certified voting results of the Annual Meeting of Stockholders (the "Annual Meeting"). In addition, Scop

      1/10/22 8:30:00 AM ET
      $SCPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DR. MORRIS C. LASTER WINS PROXY CONTEST AS STOCKHOLDERS ELECT HIS NOMINEES TO SCOPUS BIOPHARMA INC. BOARD OF DIRECTORS

      NEW YORK and JERUSALEM, Jan. 6, 2022 /PRNewswire/ -- Dr. Morris C. Laster ("Dr. Laster"), who, together with other proxy participants, beneficially owns 6,006,000 shares of common stock, par value $0.001, of Scopus BioPharma Inc. (NASDAQ:SCPS) ("Scopus" or the "Company"), announced today that stockholders of the Company have elected Dr. Laster's two director nominees, Mordechai Saar Hacham and Joshua Levine to the Company's Board of Directors at the Company's 2021 Annual Meeting of Stockholders (the "Annual Meeting"). First Coast Results, Inc., the independent inspector of elections appointed by the Company for the Annual Meeting, today certified the final results of the election reporting t

      1/6/22 7:00:00 AM ET
      $SCPS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCPS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Benchmark initiated coverage on Scopus BioPharma with a new price target

      Benchmark initiated coverage of Scopus BioPharma with a rating of Buy and set a new price target of $20.00

      2/16/21 8:08:22 AM ET
      $SCPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • The Benchmark Company initiated coverage on Scopus BioPharma with a new price target

      The Benchmark Company initiated coverage of Scopus BioPharma with a rating of Speculative Buy and set a new price target of $20.00

      2/16/21 7:40:13 AM ET
      $SCPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Benchmark initiated coverage on Scopus BioPharma

      Benchmark initiated coverage of Scopus BioPharma with a rating of Buy

      2/16/21 7:25:31 AM ET
      $SCPS
      Biotechnology: Pharmaceutical Preparations
      Health Care